MR imaging and PET using 2-Deoxy-2-[18F]fluoroglucose (FDG) are both useful in the evaluation of gynecologic malignancies. MR imaging is superior for local staging of disease whereas fludeoxyglucose FDG PET is superior for detecting distant metastases. Integrated PET/MR imaging scanners have great promise for gynecologic malignancies by combining the advantages of each modality into a single scan. This article reviews the technology behind PET/MR imaging acquisitions and technical challenges relevant to imaging the pelvis. A dedicated PET/MR imaging protocol; the roles of PET and MR imaging in cervical, endometrial, and ovarian cancers; and future directions for PET/MR imaging are discussed.
Keywords: Cervical cancer; Endometrial cancer; Gynecology; MR imaging; Ovarian cancer; PET; PET/MR imaging.
Copyright © 2017 Elsevier Inc. All rights reserved.